Venatorx Pharmaceuticals – The Drug Hunter Flying Under the Radar

Company to Watch – Venatorx Pharmaceuticals by Marie Daghlian In 2010, Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a new company focused on antibiotics, and named it Venatorx, which loosely translated means “Drug Hunter.” They didn’t have anything tangible—no money, assets, or facilities—just ideas that they threw out to each other […]

Read More

Venatorx Pharmaceuticals – The Drug Hunter Flying Under the Radar

Company to Watch – Venatorx Pharmaceuticals by Marie Daghlian In 2010, Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a new company focused on antibiotics, and named it Venatorx, which loosely translated means “Drug Hunter.” They didn’t have anything tangible—no money, assets, or facilities—just ideas that they threw out to each other […]

Read More

Venatorx Pharmaceuticals – The Drug Hunter Flying Under the Radar

Company to Watch – Venatorx Pharmaceuticals by Marie Daghlian In 2010, Drs. Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a new company focused on anti-infectives, and named it Venatorx, which loosely translated means “Drug Hunter.” Their ambition was to invent novel classes of antibiotics with novel mechanisms of action. And this […]

Read More

Venatorx Pharmaceuticals – The Drug Hunter Flying Under the Radar

Company to Watch – Venatorx Pharmaceuticals by Marie Daghlian In 2010, Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a new company focused on antibiotics, and named it Venatorx, which loosely translated means “Drug Hunter.” They didn’t have anything tangible—no money, assets, or facilities—just ideas that they threw out to each other […]

Read More

The Big4Bio Company to Watch Program
May 2021: Venatorx Pharmaceuticals

THE COMPANY/THE MISSION The Drug Hunter Flying Under the Radar In 2010, Drs. Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a company focused on anti-infectives; they named it Venatorx, which loosely translated means “Drug Hunter.”     THE PIPELINE PEOPLE/LEADERSHIP THE FUTURE   To learn more about being a feature company […]

Read More

The Big4Bio Company to Watch Program

The Big4Bio Company to Watch program is a month-long sponsored showcase that enables life science companies to give a unique and special perspective about their therapies, leaders, missions and more presented over multiple media platforms and partners, enabling an unrivaled outreach opportunity. This is an opportunity exclusively for life science organizations based, or with locations […]

Read More

SPOTLIGHT: Big4Bio:SFBay 2020 Year-in-Review

Welcome to the 2020 Big4Bio Year-in-Review for the San Francisco Bay Area! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in SFBay’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about the Bay Area’s life […]

Read More

SPOTLIGHT: Big4Bio:San Diego 2020 Year-in-Review

Welcome to the 2020 Big4Bio Year-in-Review for the San Diego region! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in San Diego’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about San Diego’s life sciences […]

Read More

SPOTLIGHT: Big4Bio:Boston 2020 Year-in-Review

Welcome to the 2020 Big4Bio Year-in-Review for the Boston area! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in Greater Boston’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about Greater Boston’s life sciences industry […]

Read More

SPOTLIGHT: Big4Bio:Philadelphia 2020 Year-in-Review

Welcome to the 2020 Big4Bio Year-in-Review for the Philadelphia area! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in Philadelphia’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about Greater Philadelphia’s life sciences industry The […]

Read More

Spotlight Q&A: TFF Pharmaceuticals – Innovative Drug Formulation May Expand Geographic Reach of COVID-19 Vaccines and Treatments

LaVoieHealthScience Client Spotlight Following is a Q&A with Glenn Mattes, President, CEO and Director of TFF Pharmaceuticals (Nasdaq: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform. Welcome to Big4Bio, Mr. Mattes. Can you share with our readers what is important about […]

Read More

Spotlight Q&A: John Hallinan, Chief Development Officer, Danforth Advisors

John Hallinan is the newly-named Chief Development Officer of Danforth Advisors, the life science industry’s leading resource for operational accounting, finance support and strategic CFO advisory. He was previously Chief Business Officer at Massachusetts Biotechnology Council (MassBio), representing the world’s premier life sciences hub, where he led efforts to catalyze early-stage innovation. He has more […]

Read More

Spotlight Q&A: John Hallinan, Chief Development Officer, Danforth Advisors

John Hallinan is the newly-named Chief Development Officer of Danforth Advisors, the life science industry’s leading resource for operational accounting, finance support and strategic CFO advisory. He was previously Chief Business Officer at Massachusetts Biotechnology Council (MassBio), representing the world’s premier life sciences hub, where he led efforts to catalyze early-stage innovation. He has more […]

Read More

BigBio Communications Launches The BioCalendar, The Premier Industry Calendar for Life Science Conferences and Events

SAN FRANCISCO–(BUSINESS WIRE)–BigBio Communications, developer of the life science industry news aggregator Big4Bio, proudly announces the launch of The BioCalendar (TheBioCalendar.com), an exclusive event listing platform for the global healthcare and biopharmaceutical industry. The BioCalendar was created to be the comprehensive calendar and guide for healthcare and life science industry event attendees worldwide, and also […]

Read More

Spotlight Q&A: Outlook Therapeutics — Developing First Ophthalmic Formulation of Bevacizumab for FDA Approval

LaVoieHealthScience Client Spotlight Following is a Q&A with Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics (NASDAQ: OTLK), a late-stage clinical biotech company focused on developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg to treat wet age-related macular degeneration (wet AMD) and other retinal diseases.  By way of background for our readers, age-related macular […]

Read More